JPH09506431A - チャペロニン10 - Google Patents
チャペロニン10Info
- Publication number
- JPH09506431A JPH09506431A JP7515294A JP51529495A JPH09506431A JP H09506431 A JPH09506431 A JP H09506431A JP 7515294 A JP7515294 A JP 7515294A JP 51529495 A JP51529495 A JP 51529495A JP H09506431 A JPH09506431 A JP H09506431A
- Authority
- JP
- Japan
- Prior art keywords
- cpn10
- amino acid
- acid sequence
- peptide
- epf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(i)cpn10に対する抗体を産生せしめ; (ii)この抗体をcpn10の含有の可能性のある生物体液サンプルと反応せしめ; (iii)cpn10−抗体複合体の生成から起きるシグナル増幅により、このサンプル 中のcpn10の存在を検出する: 各工程を含む血清または他の生物体液中のcpn10の検出方法。 2.抗体が融合タンパク質GST/cpn10またはcpn10に由来するタンパク 質に対して産生されるものである、請求項1記載の方法。 3.cpn10の含有の可能性のある生物体液サンプルをリンパ球、抗リンパ球 血清および補体と異種赤血球の存在下反応させ、ロゼット形成を阻害する抗リン パ球血清を定量することによりcpn10の存在を決定する工程を含む、ロゼット 阻害検定を使用した血清または他の生物体液中のcpn10の検出方法。 4.cpn10を被験哺乳類に投与する工程を含む、細胞成長または免疫抑制を 促進する方法。 5.傷または組織障害に罹患している被験動物にcpn10を投与する工程を含 む、傷治癒、組織修復または組織再生を促進するための、請求項4記載の方法。 6.自己免疫疾患に罹患している被験動物にcpn10を投与する工程を含む、 自己免疫疾患の処置のための、請求項4記載の方法。 7.移植片を移植された被験動物にcpn10を投与する工程を含む、器官また は皮膚移植片生存率を促進するための、請求項4記載の方法。 8.被験動物にcpn10を投与する工程を含む、炎症状態の処置に使用するた めの、請求項4記載の方法。 9.被験動物にcpn10を投与する工程を含む、アレルギー性疾患の処置に使 用するための、請求項4記載の方法。 10.被験動物にcpn10を投与する工程を含む、不妊症の予防または流産の 予防に使用するための、請求項4記載の方法。 11.配列 を有する、組換えcpn10。 12.アミノ酸配列AGQAFRKFLPLを有する、ペプチド。 13.単一アミノ酸欠損、添加または置換を含む、アミノ酸配列Ac−AGQ AFRKFLPLを有する、ペプチド。 14.単一アミノ酸欠損、添加または置換を含む、アミノ酸配列EKSQGK VLQATを有する、ペプチド。 15.単一アミノ酸欠損、添加または置換を含む、アミノ酸配列A1AGQA FRKFLPLA2(式中、A1およびA2はアミノ酸配列である)を有する、ペプ チド。 16.単一アミノ酸欠損、添加または置換を含む、アミノ酸配列AGQAFR KFLPLA2(式中、A2はアミノ酸配列である)を有する、ペプチド。 17.単一アミノ酸欠損、添加または置換を含む、アミノ酸配列A1AGQA FRKFLPL(式中、A1はアミノ酸配列である)を有する、ペプチド。 18.単一アミノ酸欠損、添加または置換を含む、アミノ酸配列Ac−A1A GQAFRKFLPLA2(式中、A1およびA2はアミノ酸配列である)を有する 、ペプチド。 19.単一アミノ酸欠損、添加または置換を含む、アミノ酸配列Ac−AGQ AFRKFLPLA2(式中、A2はアミノ酸配列である)を有する、ペプチド。 20.単一アミノ酸欠損、添加または置換を含む、アミノ酸配列Ac−A1A GQAFRKFLPL(式中、A1はアミノ酸配列である)を有する、ペプチド。 21.単一アミノ酸欠損、添加または置換を含む、アミノ酸配列A1EKSQ GKVLQATA2(式中、A1およびA2はアミノ酸配列である)を有する、ペプ チド。 22.単一アミノ酸欠損、添加または置換を含む、アミノ酸配列EKSQGK VLQATA2(式中、A2はアミノ酸配列である)を有する、ペプチド。 23.単一アミノ酸欠損、添加または置換を含む、アミノ酸配列A1EKSQ GKVLQAT(式中A1はアミノ酸配列である)を有する、ペプチド。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPM270593 | 1993-11-30 | ||
AU2705 | 1994-09-16 | ||
AUPM8234A AUPM823494A0 (en) | 1994-09-16 | 1994-09-16 | Diagnostic and therapeutic uses of chaperonin 10 |
AU8234 | 1994-09-16 | ||
PCT/AU1994/000740 WO1995015338A1 (en) | 1993-11-30 | 1994-11-30 | Chaperonin 10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003319869A Division JP3986481B2 (ja) | 1993-11-30 | 2003-09-11 | シャペロニン10 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09506431A true JPH09506431A (ja) | 1997-06-24 |
JP3545408B2 JP3545408B2 (ja) | 2004-07-21 |
Family
ID=25644587
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51529695A Expired - Fee Related JP3987104B2 (ja) | 1993-11-30 | 1994-11-30 | シャペロニン10のアンタゴニスト |
JP51529495A Expired - Fee Related JP3545408B2 (ja) | 1993-11-30 | 1994-11-30 | シャペロニン10 |
JP2003319869A Expired - Fee Related JP3986481B2 (ja) | 1993-11-30 | 2003-09-11 | シャペロニン10 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51529695A Expired - Fee Related JP3987104B2 (ja) | 1993-11-30 | 1994-11-30 | シャペロニン10のアンタゴニスト |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003319869A Expired - Fee Related JP3986481B2 (ja) | 1993-11-30 | 2003-09-11 | シャペロニン10 |
Country Status (11)
Country | Link |
---|---|
US (3) | US6113899A (ja) |
EP (2) | EP0731811B1 (ja) |
JP (3) | JP3987104B2 (ja) |
AT (1) | ATE282634T1 (ja) |
AU (2) | AU684577B2 (ja) |
CA (1) | CA2177179C (ja) |
DE (1) | DE69434137T2 (ja) |
ES (1) | ES2233938T3 (ja) |
NZ (2) | NZ276672A (ja) |
PT (1) | PT731811E (ja) |
WO (2) | WO1995015339A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002535286A (ja) * | 1999-01-20 | 2002-10-22 | ザ ユニバーシティ オブ クイーンズランド | シャペロニン10及びβ−インターフェロンによる多発性硬化症の治療方法 |
JP2006508099A (ja) * | 2002-11-06 | 2006-03-09 | キュビオ リミテッド | シャペロニン10免疫抑制 |
JP2006514001A (ja) * | 2002-11-08 | 2006-04-27 | ヘルパーバイ セラピューティクス リミテッド | 痛み軽減薬剤 |
JP2008214347A (ja) * | 2000-11-17 | 2008-09-18 | Helperby Therapeutics Ltd | 生物材料およびその使用 |
JP2009528297A (ja) * | 2006-03-02 | 2009-08-06 | シーバイオ リミテッド | 抗原提示細胞の機能の調節による免疫応答の制御 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69434137T2 (de) * | 1993-11-30 | 2005-12-01 | The University Of Queensland, Santa Lucia | Chaperonin 10 |
AU751359B2 (en) * | 1997-07-10 | 2002-08-15 | Medical Research Council | Chaperone fragments |
US6007821A (en) * | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
US6475490B1 (en) | 1998-10-19 | 2002-11-05 | Fordham University | Compositions and methods for promoting tissue repair using heat shock proteins |
ES2307767T3 (es) * | 2001-06-27 | 2008-12-01 | Janssen Pharmaceutica Nv | Ensayos con el receptor epf, compuestos y composiciones terapeuticas. |
NZ548985A (en) * | 2004-01-16 | 2010-02-26 | Cbio Ltd | Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion |
EP2463307A1 (en) | 2005-08-31 | 2012-06-13 | CBIO Limited | Modified chaperonin 10 |
CN101330922A (zh) * | 2005-10-20 | 2008-12-24 | 悉生物有限公司 | 超敏的治疗 |
AU2006303826B2 (en) * | 2005-10-20 | 2012-07-19 | Cbio Limited | Treatment of hypersensitivity |
CN102015757B (zh) | 2008-04-11 | 2015-12-02 | 悉生物有限公司 | 修饰的Cpn10以及PRR信号 |
CN102711793A (zh) * | 2009-10-09 | 2012-10-03 | 悉生物有限公司 | 伴侣蛋白10变异体 |
US20110243921A1 (en) * | 2010-03-30 | 2011-10-06 | Cbio Limited | Prevention and treatment of cutaneous lupus erythematosus |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986005498A1 (en) * | 1985-03-12 | 1986-09-25 | University Of Queensland | Method for detecting early pregnancy factor (epf) in mammals, purifying epf and method for producing a monoclonal antibody |
AU599021B2 (en) * | 1985-03-12 | 1990-07-12 | University Of Queensland, The | Method for detecting early pregnancy factor (epf) in mammals,purifying epf and method for producing a monoclonal antibody |
AU1086988A (en) * | 1986-12-22 | 1988-07-15 | University Of Queensland, The | Method of treatment of mammals using antibodies to early pregnancy factor (epf) |
JPH02501160A (ja) * | 1986-12-22 | 1990-04-19 | ユニバーシティー オブ クイーンスランド | 早期妊娠因子(epf)に対する抗体を使用する哺乳動物の治療方法 |
DE69434137T2 (de) * | 1993-11-30 | 2005-12-01 | The University Of Queensland, Santa Lucia | Chaperonin 10 |
-
1994
- 1994-11-30 DE DE69434137T patent/DE69434137T2/de not_active Expired - Lifetime
- 1994-11-30 JP JP51529695A patent/JP3987104B2/ja not_active Expired - Fee Related
- 1994-11-30 EP EP95902003A patent/EP0731811B1/en not_active Expired - Lifetime
- 1994-11-30 EP EP95902005A patent/EP0733071A4/en not_active Withdrawn
- 1994-11-30 NZ NZ276672A patent/NZ276672A/en not_active IP Right Cessation
- 1994-11-30 PT PT95902003T patent/PT731811E/pt unknown
- 1994-11-30 ES ES95902003T patent/ES2233938T3/es not_active Expired - Lifetime
- 1994-11-30 WO PCT/AU1994/000742 patent/WO1995015339A1/en not_active Application Discontinuation
- 1994-11-30 AU AU11034/95A patent/AU684577B2/en not_active Ceased
- 1994-11-30 CA CA002177179A patent/CA2177179C/en not_active Expired - Fee Related
- 1994-11-30 AU AU11036/95A patent/AU684578B2/en not_active Ceased
- 1994-11-30 AT AT95902003T patent/ATE282634T1/de not_active IP Right Cessation
- 1994-11-30 JP JP51529495A patent/JP3545408B2/ja not_active Expired - Fee Related
- 1994-11-30 WO PCT/AU1994/000740 patent/WO1995015338A1/en active IP Right Grant
- 1994-11-30 NZ NZ276670A patent/NZ276670A/en not_active IP Right Cessation
-
1996
- 1996-05-29 US US08/654,618 patent/US6113899A/en not_active Expired - Lifetime
-
1999
- 1999-02-23 US US09/255,703 patent/US6417334B1/en not_active Expired - Fee Related
-
2002
- 2002-05-21 US US10/151,006 patent/US7358329B2/en not_active Expired - Fee Related
-
2003
- 2003-09-11 JP JP2003319869A patent/JP3986481B2/ja not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002535286A (ja) * | 1999-01-20 | 2002-10-22 | ザ ユニバーシティ オブ クイーンズランド | シャペロニン10及びβ−インターフェロンによる多発性硬化症の治療方法 |
JP4691257B2 (ja) * | 1999-01-20 | 2011-06-01 | ザ ユニバーシティ オブ クイーンズランド | シャペロニン10及びβ−インターフェロンによる多発性硬化症の治療方法 |
JP2008214347A (ja) * | 2000-11-17 | 2008-09-18 | Helperby Therapeutics Ltd | 生物材料およびその使用 |
JP4648956B2 (ja) * | 2000-11-17 | 2011-03-09 | ヘルパーバイ セラピューティクス リミテッド | 生物材料およびその使用 |
JP2006508099A (ja) * | 2002-11-06 | 2006-03-09 | キュビオ リミテッド | シャペロニン10免疫抑制 |
JP4716731B2 (ja) * | 2002-11-06 | 2011-07-06 | シーバイオ リミテッド | シャペロニン10免疫抑制 |
JP2006514001A (ja) * | 2002-11-08 | 2006-04-27 | ヘルパーバイ セラピューティクス リミテッド | 痛み軽減薬剤 |
JP2009528297A (ja) * | 2006-03-02 | 2009-08-06 | シーバイオ リミテッド | 抗原提示細胞の機能の調節による免疫応答の制御 |
Also Published As
Publication number | Publication date |
---|---|
JPH09505811A (ja) | 1997-06-10 |
EP0733071A4 (en) | 1997-02-26 |
ES2233938T3 (es) | 2005-06-16 |
AU1103695A (en) | 1995-06-19 |
DE69434137D1 (en) | 2004-12-23 |
JP3986481B2 (ja) | 2007-10-03 |
US6113899A (en) | 2000-09-05 |
US6417334B1 (en) | 2002-07-09 |
AU684578B2 (en) | 1997-12-18 |
EP0733071A1 (en) | 1996-09-25 |
US20030175280A1 (en) | 2003-09-18 |
WO1995015339A1 (en) | 1995-06-08 |
CA2177179C (en) | 2006-10-17 |
US7358329B2 (en) | 2008-04-15 |
JP3987104B2 (ja) | 2007-10-03 |
AU1103495A (en) | 1995-06-19 |
ATE282634T1 (de) | 2004-12-15 |
WO1995015338A1 (en) | 1995-06-08 |
NZ276672A (en) | 1998-01-26 |
JP3545408B2 (ja) | 2004-07-21 |
CA2177179A1 (en) | 1995-06-08 |
AU684577B2 (en) | 1997-12-18 |
EP0731811B1 (en) | 2004-11-17 |
EP0731811A1 (en) | 1996-09-18 |
EP0731811A4 (en) | 2003-05-28 |
PT731811E (pt) | 2005-04-29 |
NZ276670A (en) | 1998-01-26 |
DE69434137T2 (de) | 2005-12-01 |
JP2004067698A (ja) | 2004-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3545408B2 (ja) | シャペロニン10 | |
US8338136B2 (en) | Method of producing a paralytic peptide | |
JP2000055916A (ja) | インスリン依存性糖尿病の診断と治療 | |
JPH11192092A (ja) | 不妊と避妊のための透明帯抗原と抗体の調製法及び使用 | |
JP3220451B2 (ja) | ブタクサからのアレルゲン蛋白質およびそれらの使用 | |
CA2176948C (en) | Chaperonin 10 | |
US7485622B2 (en) | Paralytic peptide for use in neuromuscular therapy | |
JPH02306996A (ja) | 酸性線維芽細胞成長因子の抗体,その用途およびペプチド | |
JPWO2002072628A1 (ja) | 生理活性を有するポリペプチドとこのポリペプチドをコードするポリヌクレオチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20031202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040115 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040309 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040408 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080416 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090416 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090416 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100416 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110416 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120416 Year of fee payment: 8 |
|
LAPS | Cancellation because of no payment of annual fees |